InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Stock Free
05/28/09 9:04 AM
profile icon
Stock Free
05/28/09 9:00 AM
profile icon
bigworld Free
06/09/06 11:33 AM
profile icon
TradeWinds Free
06/09/06 7:45 AM
profile icon
bigworld Free
06/08/06 3:04 PM
profile icon
jkids210 Free
06/07/06 1:13 AM
profile icon
jkids210 Free
05/30/06 2:44 PM
profile icon
Golden Cross Free
05/15/06 9:04 PM
profile icon
bigworld Free
05/06/06 12:25 PM
profile icon
TradeWinds Free
05/06/06 11:03 AM
profile icon
bigworld Free
05/05/06 12:22 PM
profile icon
phillysea Free
05/02/06 11:26 AM
profile icon
trade1 Terminated
05/01/06 5:28 PM
profile icon
bigworld Free
04/25/06 11:36 AM
profile icon
TradeWinds Free
04/25/06 8:20 AM
profile icon
MasterCMc Free
04/25/06 1:49 AM
profile icon
trade1 Terminated
04/24/06 11:56 PM
profile icon
trade1 Terminated
04/24/06 8:26 PM
profile icon
bigworld Free
04/24/06 6:58 PM
profile icon
trade1 Terminated
04/24/06 6:10 PM
profile icon
bigworld Free
04/24/06 1:58 PM

Axonyx Inc (AXYX) RSS Feed

Followers
0
Posters
9
Posts (Today)
0
Posts (Total)
22
Created
04/24/06
Type
Free
Moderators
Researcher Reports Data on Effects of Posiphen(TM) on Human Neuronal Stem Cells Monday April 24, 8:30 am ET Posiphen May Support Stem Cell Transplantation in Alzheimer's Disease NEW YORK--(BUSINESS WIRE)--April 24, 2006--Axonyx Inc. (NASDAQ: AXYX - News) today announced the results of an independent study showing that Posiphen increased the ability of transplanted human neuronal stem cells (HNSC) to differentiate into neurons in APP transgenic mice, a model of Alzheimer's disease (AD) in humans. The research was reported by Kiminobu Sugaya, Ph.D., Professor of Molecular Biology, Biomolecular Sciences Center, University of Central Florida, Orlando, Florida at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer's Disease held April 19 - 22, 2006 in Geneva, Switzerland. ADVERTISEMENT Dr. Sugaya's research showed that when APP transgenic mice had been pre-treated with Posiphen, transplanted HNSC start to differentiate into neurons in the brain area where they are needed. When HNSC were transplanted into the brains of APP transgenic mice in the absence of Posiphen, HNSC did not differentiate into neurons. Dr. Sugaya attributed this effect to Posiphen's ability to decrease the synthesis of amyloid precursor protein (APP). Posiphen may support and augment production of the new neurons through the suppression of APP production in the brain. The differentiation of stem cells into functioning neurons is critical to the success of stem cell therapy of AD. "Although a better understanding of the mechanisms of APP function HNSC biology may be needed", stated Dr. Kiminobu Sugaya, "regulation of APP levels by a combination of Posiphen and stem cell treatments could be a promising strategy to treat AD." About Posiphen(TM) Posiphen is in Phase I clinical development by Axonyx for the potential treatment of AD progression and is the positive isomer of Phenserine. Posiphen treatment, similar to Phenserine, has been shown to lower secreted and cellular APP and secreted Amyloid beta (A beta) levels in neuronal cells in culture as well as in vivo studies in mice, where brain levels of both APP and A beta were significantly and dose-dependently lowered by Posiphen over a wide range of doses that were well tolerated. About Alzheimer's Disease Alzheimer's disease is typified by a progressive impairment in memory, cognition and emotional disturbances that result from the dysfunction and death of neurons in the brain. This pathology is considered, in part, to be the result of the over production and accumulation of beta amyloid (A beta) in and between neurons. Beta amyloid, a result of the cleavage of APP, subsequently aggregates to form plaques that are a microscopic hallmark of AD and have been postulated to have a causative role in AD. About Axonyx Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease; Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer's disease (AD); Posiphen(TM) - a potential disease progression treatment for AD now in Phase I; and BisNorCymcerine (BNC) - a potential symptomatic treatment of severe AD in the pre-Investigational New Drug (IND) stage.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
AXYX Latest News
  • No Recent News Available for this company!
New Post